AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-10. (cancelled)

11. (currently amended) A method of administering to a patient a sublingual pharmaceutical formulation for the treatment of inflammatory symptoms of various type, ~~generally associated with pain and fever,~~ said pharmaceutical formulation comprising at least one non-steroidal anti-inflammatory agent FANS, wherein the therapeutic dose of said anti-inflammatory agent in said sublingual formulation is ~~drastically~~ reduced in comparison with the therapeutic dose of the same anti-inflammatory agent in a pharmaceutical formulation for oral administration, which provides the same therapeutic effect of treatment of inflammatory symptoms.

12. (previously presented) The method according to claim 11, in which the FANS agent is capable of being absorbed by the oral mucosa.

13. (previously presented) The method according to claim 11, in which the FANS agent is selected among: nimesulide, ketoprofen, ibuprofen, paracetamol, diclofenac, naproxen, ketorolac, tenoxicam or pyroxicam.

14. (previously presented) The method according to claim 11, in which said sublingual pharmaceutical formulation further contains a water soluble excipient and/or a crystalline water insoluble excipient with a disintegrating function.

15. (previously presented) The method according to claim 14, in which said water soluble excipient is mannitol.

16. (previously presented) The method according to claim 14, in which said crystalline water insoluble excipient with a disintegrating function is microcrystalline cellulose.

17. (previously presented) The method according to claim 11, in which said sublingual pharmaceutical formulation further contains a lubricant.

18. (previously presented) The method according to claim 17, in which said lubricant is magnesium stearate and/or PEG 6000 powder.

19. (previously presented) The method according to claim 11, in which said sublingual pharmaceutical formulation further contains a sweetener.

20. (previously presented) The method according to claim 19, in which said sweetener is sodium saccharate.

21. (previously presented) The method according to claim 11, in which said sublingual pharmaceutical formulation is in a pharmaceutical form selected among: gel, granulate, powder, freeze-dried product, pressed capsule or pill.